Interaction Checker
Do Not Coadminister
Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF)
Oxcarbazepine
Quality of Evidence: Very Low
Summary:
Coadministration is not recommended. Oxcarbazepine induces CYP3A4 and UGT and is expected to decrease both tenofovir alafenamide and bictegravir exposures, which may result in loss of therapeutic effect and development of resistance. Alternative anticonvulsants should be considered. A case report describes a person living with HIV on bictegravir/tenofovir alafenamide/emtricitabine (50/50/200 mg once daily) and oxcarbazepine (150 mg twice daily) who remained virologically suppressed. The observation is likely explained by the lower dose of oxcarbazepine given that oxcarbazepine has a dose dependent inducing effect.
Description:
Copyright © 2025 The University of Liverpool. All rights reserved.